Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
RAPT Therapeutics, Inc. (RAPT)
|
Add to portfolio |
|
|
|
| Price: |
$39.48
| | Metrics |
| OS: |
34.4
|
M
| |
-55
|
% ROE
|
| Market cap: |
$1.36
|
B
| |
-69
|
% ROIC
|
|
Net cash:
|
$50.2
|
M
| |
$1.46
|
per share
|
|
EV:
|
$1.31
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
($109)
|
M
| |
|
|
| EPS |
($2.85)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-05-22 | Dec-31-21 | Dec-05-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 |
| Revenues | 1.5 | 1.5 | 3.8 | 3.8 | 5.0 | 0.0 | 73.9 | 58.7 |
| Revenue growth | -60.0% | -60.0% | -24.4% | | | -100.0% | 26.0% | |
| Cost of goods sold | 0.0 | 87.3 | 0.0 | 73.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 1.5 | -85.8 | 3.8 | -69.2 | 5.0 | 0.0 | 73.9 | 58.7 |
| Gross margin | 100.0% | -5618.5% | 100.0% | -1815.1% | 100.0% | | 100.0% | 100.0% |
| Selling, general and administrative | 87.3 | | 73.0 | | | | | |
| Research and development | | | | | 45.5 | 34.9 | 31.8 | 25.6 |
| General and administrative | | 20.2 | | 16.0 | 12.8 | 8.7 | 5.2 | 3.7 |
| EBIT | -81.9 | -85.8 | -69.2 | -69.2 | -53.2 | -43.6 | 36.9 | 29.3 |
| EBIT margin | -5362.2% | -5618.5% | -1814.8% | -1815.1% | -1055.4% | | 50.0% | 50.0% |
| Pre-tax income | -83.8 | -83.8 | -69.2 | -69.2 | -51.9 | -42.3 | 36.1 | -29.1 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 1.0 | 0.7 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | | | 0.0% | |
| Net income | -83.8 | -83.8 | -69.2 | -69.2 | -52.9 | -43.0 | 36.1 | -29.1 |
| Net margin | -5490.4% | -5490.4% | -1814.9% | -1814.9% | -1049.0% | | 48.9% | -49.6% |
| |
| Diluted EPS | ($2.58) | ($2.58) | ($2.53) | ($2.53) | ($2.19) | ($9.89) | $58.09 | ($67.45) |
| Shares outstanding (diluted) | 32.5 | 32.5 | 27.4 | 27.4 | 24.1 | 4.3 | 0.6 | 0.4 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|